UK Myasthenia Gravis Therapeutics Market Report 2023 to 2030

UK Myasthenia Gravis Therapeutics Market Analysis

$ 3999

UK myasthenia gravis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The myasthenia gravis market engages in all of these activities, including regulatory approvals, the introduction of new products, the purchase of other companies, and joint ventures with them. These strategies will definitely contribute to the growth of the global industry. Major global players in this market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.

ID: IN10GBRD048 CATEGORY: Rare Diseases GEOGRAPHY: UK AUTHOR: Sakshi Mantri

Buy Now

UK Myasthenia Gravis Therapeutics Market Analysis Summary

UK Myasthenia Gravis Therapeutics Market is valued at around $44.2 Mn in 2022 and is projected to reach $62.86 Mn by 2030, exhibiting a CAGR of 4.5% during the forecast period 2023-2030.

If you have myasthenia gravis, any muscle you can control will quickly weaken and tire. It happens when the regular flow of information between neurons and muscles breaks down. Medication can help with the signs and symptoms of myasthenia gravis, which include muscle weakness in the arms or legs, double vision, drooping eyelids, and difficulties breathing, speaking, chewing, and swallowing. The illness, however, has no known treatment. The myasthenia gravis market engages in all of these activities, including regulatory approvals, the introduction of new products, the purchase of other companies, and joint ventures with them. These strategies will definitely contribute to the growth of the global industry. Major global players in this market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.

Market Dynamics

Market Growth Drivers

As more people develop neuromuscular conditions affecting the muscles, neuromuscular junctions, peripheral nerves, nerve plexuses, spinal nerve roots, and/or cranial and spinal motor neurons, the market for treatments will grow faster. Additionally, it is projected that increased patient understanding of the condition will promote market growth.

Additional growth factors that help the market rise include the continuing clinical trials that pharmaceutical companies are performing to develop innovative medicines. The strong pipeline of possible drugs and the range of options will drive even more growth in the market for myasthenia gravis therapy.

The market for myasthenia gravis will also expand due to advancements in medical technology, expanding government initiatives to increase cancer awareness, and increased public support.

Market Restraints

The market for myasthenia gravis disease will continue to grow, but it may take longer due to the high price of associated drugs and therapies as well as competition from off-label drugs. The high dose combination would limit the market's growth because it also causes severe muscle cramping in myasthenia gravis sufferers. Due to the limited supply of FDA-approved drugs over the projected period, the market would encounter further difficulties.

Developments of UK Myasthenia Gravis Therapeutics Market

Argenx began spreading the word about myasthenia gravis in June 2020. The campaign's launchpads included a virtual conference, light-up events held around the country, the launch of a patient website, and the announcement of a forthcoming documentary.

Key players

Alexion Pharmaceuticals Pfizer Shire Sanofi Novartis Catalyst Pharmaceuticals Intercept Pharmaceuticals Acorda Therapeutics Teva Pharmaceutical Industries Catalyst Biosciences

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK Myasthenia Gravis Therapeutics Market Segmentation

By Diagnosis

Edrophonium Test
Blood Test
Repetitive Nerve Stimulation
Single-fiber electromyography (EMG)
Others

By Treatment

Cholinesterase Inhibitors
Corticosteroids
Immunosuppressants
Plasmapheresis
Autologous Hematopoietic Stem Cell
Transplantation (HSCT)
Surgery

By End-user

Hospital and Clinics
Diagnostic Laboratories
Homecare

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.